Durvalumab (anti-PD-L1)
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2013 |
| Sku # | A2013-1mg*25 |
| Pricing | 1mg*25, $2127.00 |
Citations for this product:
-
bioRxiv - Cancer Biology 2022Quote: ... or Durvalumab (anti-PD-L1, cat# A2013 from Selleck Chemicals).